WhiteHawk Minerals Corp. filed a current report on November 2, 2026, disclosing that its subsidiary entered into a Third Amendment to its Amended and Restated Credit Agreement on October 27, 2026, to permit the issuance of Series E and Series F Preferred Stock.
Outdoor Specialty Products, Inc. filed a Form 8-K on November 2, 2026, reporting that on October 27, 2026, it filed a Certificate of Designation with the Nevada Secretary of State establishing a new Series A Preferred Stock series.
Elme Communities filed a current report on November 2, 2026, disclosing the Board-approved termination of retention agreements with three senior officers and the NYSE delisting of its common shares of beneficial interest, both connected to the company's planned dissolution on November 6, 2026.
Viper Energy, Inc. filed a Form 8-K with the SEC on November 2, 2026, reporting financial and operating results for the third quarter ended September 30, 2026, and announcing a third quarter 2026 cash dividend.
Avis Budget Group, Inc. filed a Form 8-K on November 2, 2026, disclosing that two of its wholly-owned subsidiaries delivered a notice to redeem all $350,000,000 of their 5.750% Senior Notes due July 2027, with the full redemption scheduled for December 30, 2026.
Southwest Airlines Co. filed a current report on Form 8-K on November 2, 2026, disclosing the completion of a public offering of $1,250,000,000 in aggregate principal amount of debt securities in two tranches.
10x Genomics, Inc. filed a Form 8-K on November 2, 2026, disclosing the appointment of Ansuman Satpathy and Joseph Gilliam to its Board of Directors as Class III directors, effective October 28, 2026.
Jerash Holdings (US), Inc. filed a Form 8-K on November 2, 2026, disclosing that its subsidiary Treasure Success International Limited terminated legacy consulting agreements with entities owned by CEO Choi Lin Hung and Chairman Ng Tsze Lun and replaced them with direct employment agreements …
Theriva Biologics, Inc. filed a Form 8-K on November 2, 2026, disclosing that on October 30, 2026, the company entered into and simultaneously closed an Asset Purchase and Sale Agreement with Biossil Labs Inc. covering its SYN-004 (ribaxamase) and SYN-006 (carbapenemase) product candidates.
Franklin Financial Services Corporation, a Pennsylvania-based bank holding company trading on NASDAQ:FRAF, filed a Form 8-K on November 2, 2026, furnishing an investor presentation under Regulation FD that executives plan to use in meetings with investors and analysts.